SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-20-000053
Filing Date
2020-05-07
Accepted
2020-05-07 16:44:17
Documents
64
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20200331.htm   iXBRL 10-Q 2056137
2 EX-10.1 exhibit101amendedandre.htm EX-10.1 54840
3 EX-31.1 exhibit311q12020.htm EX-31.1 12091
4 EX-31.2 exhibit312q12020.htm EX-31.2 12131
5 EX-32.1 exhibit321q12020.htm EX-32.1 7209
6 EX-32.2 exhibit322q12020.htm EX-32.2 7300
  Complete submission text file 0001714899-20-000053.txt   7951192

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20200331.xsd EX-101.SCH 48243
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20200331_cal.xml EX-101.CAL 69772
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20200331_def.xml EX-101.DEF 246832
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20200331_lab.xml EX-101.LAB 611093
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20200331_pre.xml EX-101.PRE 393452
12 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20200331_htm.xml XML 1407012
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 20857187
SIC: 2836 Biological Products, (No Diagnostic Substances)